Fount of Information

ACROBiosystems社 Insights:Facilitating Bispecific Antibody Drug Development through Quality Control



Facilitating Bispecific Antibody Drug Development through Quality Control


Bispecific antibodies(bsAbs) are a relatively new type of drug in the field of targeted therapeutics. By binding to both CD3 and a tumor-associated antigen, these bsAbs bridge T cells and tumor cells together to initiate tumor cell death, irrespective of T cell receptor specificity, co-stimulation, or peptide antigen presentation. Furthermore, the activation of T cells by CD3 bsAbs stimulates the secretion of a wide variety of cytokines to recruit immune helper cells to further enhance the anti-tumor cell effects.

Current marketed bsAbs that have successfully received market approval

and their listed indication of use



From the concept phase to clinical trials, many companies around the world are accelerating their research and development processes of these drugs, especially CD3-targeting bsAbs. This means that quality control of bsAb drugs becomes even more critical, especially as a novel immunotherapeutic. A key reagent for these quality control studies are recombinant proteins. To support bsAb research and its relevant quality control studies, ACROBiosystems strives to provide high-quality, bioactive, and consistent recombinant proteins including CD3 and many others.


Fount of Information は、新商品、新規取扱メーカーなどの情報をいち早く紹介するコンテンツです。情報発信のスピードを重視しているコンテンツのため、現時点で法規制や取り扱いを確認できていない商品、定価を設定できていない商品があります。ご要望やご照会を受けた商品について、法令整備や在庫の充実を図ります。